If you have been weighing what to do with Corcept Therapeutics (CORT), this latest development might tip the scales. The company just announced that the FDA has accepted its New Drug Application for relacorilant in platinum-resistant ovarian cancer. This is a major regulatory milestone that places their lead candidate squarely in the spotlight. This comes after strong Phase 3 and Phase 2 trial data, where relacorilant combined with nab-paclitaxel improved both progression-free and overall survival without adding extra safety risk compared to chemotherapy alone.
Shares of Corcept have shown a multi-month rally, rising over 60% year-to-date and nearly doubling in value over the past year. Momentum appears to be building, especially as the pipeline’s late-stage success reaches key regulatory checkpoints. The stock price has steadily gained alongside annual revenue and net income growth, supplementing optimism from both current results and a future packed with advanced clinical programs.
With the FDA now officially reviewing relacorilant’s potential, the market is reacting and expectations are in flux. Are investors getting ahead of themselves, or is this opening a window where Corcept’s future growth still is not fully appreciated?
Advertisement
Most Popular Narrative: 40% Undervalued
According to the most widely followed narrative among analysts, Corcept Therapeutics is trading at a substantial discount to its estimated fair value. The consensus is that the stock remains attractively priced relative to the growth and market opportunities analysts see ahead.
Anticipated regulatory approvals for relacorilant in both hypercortisolism at the end of this year, and platinum-resistant ovarian cancer next year, supported by clinically differentiated safety and efficacy data, create major new revenue and margin expansion opportunities as the company moves past single-product dependence.
What is the engine under Corcept’s dramatic price target? This narrative is built on projections of rapid sales growth, expanding margins, and ambitious profit assumptions that most investors are not factoring in today. Hungry for the specific financial leaps and market catalysts driving this bold outlook? Discover the numbers that could reshape the valuation landscape for Corcept Therapeutics.
Looking through a different lens, evaluating Corcept's valuation against the industry using one popular earnings ratio shows the stock trades at a steep premium. This challenges the narrative of a wide margin of undervaluation. Could current optimism be running too hot?
Stay updated when valuation signals shift by adding Corcept Therapeutics to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.
Build Your Own Corcept Therapeutics Narrative
If you want to dig deeper or reach your own conclusions, you can easily craft a custom narrative in just a few minutes. Do it your way
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Corcept Therapeutics.
Looking for More Smart Investment Moves?
Why limit your gains to one company? Get ahead of the crowd and uncover investment ideas that could change your financial future by using these curated lists to spot tomorrow’s winners today.
Spot opportunities in tech’s next frontier by unleashing the potential of quantum computing advancements with the quantum computing stocks resource.
Catch companies reimagining medicine and healthcare by tapping into breakthroughs in artificial intelligence with our insider look at healthcare AI stocks.
Jump on undervalued stocks poised for growth and find unique values hiding in plain sight using our original undervalued stocks based on cash flows shortlists.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
